<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; years</title>
	<atom:link href="http://www.tapanray.in/tag/years/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Pharma Sales Post Covid-19 Lockdown</title>
		<link>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-sales-post-covid-19-lockdown</link>
		<comments>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/#comments</comments>
		<pubDate>Mon, 04 May 2020 00:00:20 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[commercial]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[customer-centricity]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[doctor]]></category>
		<category><![CDATA[fallout]]></category>
		<category><![CDATA[habit]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[lockdown]]></category>
		<category><![CDATA[long]]></category>
		<category><![CDATA[Medical]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[oldest]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient-Centricity]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Personal]]></category>
		<category><![CDATA[platforms]]></category>
		<category><![CDATA[post Covid-19]]></category>
		<category><![CDATA[preferences]]></category>
		<category><![CDATA[Promotion]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Representatives]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[selling]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[two]]></category>
		<category><![CDATA[years]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10054</guid>
		<description><![CDATA[Disruptions from Covid-19 pandemic have caused limited access to physicians for Pfizer&#8217;s marketing and sales teams have had. If ‘the novel Coronavirus pandemic hamstringing the company’s sales team,’ there could be a slowdown in new prescriptions and a sales hit in the second quarter, said the global &#8230; <a href="http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-sales-post-covid-19-lockdown/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Setting A Cost Of Time That Patients May Gain From A New Therapy</title>
		<link>http://www.tapanray.in/setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy</link>
		<comments>http://www.tapanray.in/setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy/#comments</comments>
		<pubDate>Mon, 16 Mar 2020 00:00:07 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[biopharma]]></category>
		<category><![CDATA[calculation]]></category>
		<category><![CDATA[calculator]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cost of time]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[funding]]></category>
		<category><![CDATA[human]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[prolonging]]></category>
		<category><![CDATA[quality of life]]></category>
		<category><![CDATA[quantity of life]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare diseases]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[setting]]></category>
		<category><![CDATA[Spiranza]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>
		<category><![CDATA[value]]></category>
		<category><![CDATA[years]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9916</guid>
		<description><![CDATA[Since quite some, an intense ongoing debate about setting a cost of time, often by a few months, that patients could possibly gain from a new therapy for complex diseases. The answer still remains elusive.  Meanwhile, newer therapies for treating cancer, &#8230; <a href="http://www.tapanray.in/setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/setting-a-cost-of-time-that-patients-may-gain-from-a-new-therapy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why Many Successful CEOs Don’t Want to Retire &#8211; in Pharma Too?</title>
		<link>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-many-successful-ceos-dont-want-to-retire-in-pharma-too</link>
		<comments>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/#comments</comments>
		<pubDate>Mon, 12 Nov 2018 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[70]]></category>
		<category><![CDATA[abbott]]></category>
		<category><![CDATA[Aditya]]></category>
		<category><![CDATA[Aging]]></category>
		<category><![CDATA[alkem]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Basudeo]]></category>
		<category><![CDATA[cadila]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Frazier]]></category>
		<category><![CDATA[GE]]></category>
		<category><![CDATA[HDFC]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[ITC]]></category>
		<category><![CDATA[Jack]]></category>
		<category><![CDATA[Kenneth]]></category>
		<category><![CDATA[L&T]]></category>
		<category><![CDATA[listed]]></category>
		<category><![CDATA[mandatory]]></category>
		<category><![CDATA[MD]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Miles]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Naik]]></category>
		<category><![CDATA[Narain]]></category>
		<category><![CDATA[Pankaj]]></category>
		<category><![CDATA[Patel]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[publicly]]></category>
		<category><![CDATA[Puri]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[RBI]]></category>
		<category><![CDATA[retire]]></category>
		<category><![CDATA[retirement]]></category>
		<category><![CDATA[Singh]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Welsh]]></category>
		<category><![CDATA[white]]></category>
		<category><![CDATA[years]]></category>
		<category><![CDATA[Yogeshwar]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9256</guid>
		<description><![CDATA[“On Eve of Retirement, Jack Welch Decides to Stick Around GE a Bit,” reported the Wall Street Journal (WSJ) on October 23, 2000. Nevertheless, even the legendary Jack Welsh was made no exception to GE’s mandatory retirement policy for the &#8230; <a href="http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-many-successful-ceos-dont-want-to-retire-in-pharma-too/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Does Healthcare Feature In Raisina Hill’s To-Do List?</title>
		<link>http://www.tapanray.in/does-healthcare-feature-in-raisina-hills-to-do-list/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=does-healthcare-feature-in-raisina-hills-to-do-list</link>
		<comments>http://www.tapanray.in/does-healthcare-feature-in-raisina-hills-to-do-list/#comments</comments>
		<pubDate>Mon, 27 Jun 2016 00:00:06 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2015]]></category>
		<category><![CDATA[Aushadhi]]></category>
		<category><![CDATA[beds]]></category>
		<category><![CDATA[Capitol]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[CHC]]></category>
		<category><![CDATA[community]]></category>
		<category><![CDATA[Congress]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[digital]]></category>
		<category><![CDATA[Draft]]></category>
		<category><![CDATA[DTAB]]></category>
		<category><![CDATA[economic]]></category>
		<category><![CDATA[GDP]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Hill]]></category>
		<category><![CDATA[Hospital]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infrastructure]]></category>
		<category><![CDATA[Jan]]></category>
		<category><![CDATA[joint]]></category>
		<category><![CDATA[Mantri]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[PHC]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[productive]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[pump-priming]]></category>
		<category><![CDATA[Raisina]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[session]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[technology]]></category>
		<category><![CDATA[telemedicine]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[years]]></category>
		<category><![CDATA[Yojana’]]></category>
		<category><![CDATA[‘Pradhan]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7687</guid>
		<description><![CDATA[At the Capitol Hill, while addressing the joint session of the United States Congress, on June 08, 2016, our Prime Minister Mr. Narendra Modi well articulated the following, in his inimitable style: “My to-do list is long and ambitious. It &#8230; <a href="http://www.tapanray.in/does-healthcare-feature-in-raisina-hills-to-do-list/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/does-healthcare-feature-in-raisina-hills-to-do-list/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
